Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study

Blood (2024) 144 (Supplement 1): 5153.

https://doi.org/10.1182/blood-2024-204021

Published: 2024

Journal Articles

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

Blood (2024) 143 (7): 592–596.

https://doi.org/10.1182/blood.2023022080

Published: 2024

Includes: Supplemental data

Journal Articles

High Humoral Response after Anti-Sars-Cov-2 mRNA-Based Vaccines in Patients with Active Multiple Myeloma (MM) and Relationship with Disease Status/Line of Therapy

Katia Mancuso, Elena Zamagni, Vincenza Solli, Liliana Gabrielli, Lucia Pantani, Serena Rocchi, Ilaria Rizzello, Paola Tacchetti, Alessio Fusco, Gabriella De Cicco, Margherita Ursi, Marco Talarico, Emanuele Favero, Giuliana Nepoti, Barbara Ruffini, Carolina Terragna, Tiziana Lazzarotto, Pier Luigi Zinzani, Michele Cavo

Blood (2021) 138 (Supplement 1): 4732.

https://doi.org/10.1182/blood-2021-150266

Published: 2021

Journal Articles

Negative Selective Pressure Exerted By Maintenance Therapy Promotes the Extinction of Sub-Clones Carrying High-Risk Lesions in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 1778.

https://doi.org/10.1182/blood-2019-127799

Published: 2019

Journal Articles

Serum Free Light Chain Assay As an Additional Tool for Defining Response and Progressive Disease in Immunoglobulin Secretory Multiple Myeloma

Paola Tacchetti, Serena Rocchi, Luca Dozza, Elena Zamagni, MD, Isola Caratozzolo, MD, Ilaria Rizzello, Alessio Fusco, MD, Gabriella De Cicco, MD, Lucia Pantani, MD, Katia Mancuso, Carolina Terragna, Nicoletta Testoni, Pier Luigi Luigi Zinzani, MD, Michele Cavo

Blood (2019) 134 (Supplement_1): 1796.

https://doi.org/10.1182/blood-2019-128715

Published: 2019

Journal Articles

A Maturation Index Defines Newly Diagnosed Multiple Myeloma Patients with Advanced Immunophenotypic and Molecular Differentiation Profiles Associated with Poor Prognosis

Blood (2019) 134 (Supplement_1): 1797.

https://doi.org/10.1182/blood-2019-129975

Published: 2019

Journal Articles

Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study

Blood (2019) 134 (Supplement_1): 3195.

https://doi.org/10.1182/blood-2019-124388

Published: 2019

Journal Articles

Bortezomib-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone before and after Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase 3 Gimema-MMY-3006 Study and Prognostic Score for Survival Outcomes

Blood (2018) 132 (Supplement 1): 125.

https://doi.org/10.1182/blood-2018-99-116716

Published: 2018

Journal Articles

High-Risk Cytogenetics in Newly Diagnosed Multiple Myeloma: Prognostic Relevance of Co-Segregations and Analysis of the Role of Double Versus Single Autotransplantation

Blood (2017) 130 (Supplement 1): 394.

https://doi.org/10.1182/blood.V130.Suppl_1.394.394

Published: 2017

Journal Articles

A Randomized Study of Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Cyclophosphamide-Dexamethasone Induction in Newly Diagnosed Myeloma Patients Eligible for Transplant: High Efficacy in High- and Standard-Risk Patients

Blood (2017) 130 (Supplement 1): 4541.

https://doi.org/10.1182/blood.V130.Suppl_1.4541.4541

Published: 2017

Journal Articles

A Branching Evolution Model at Relapse Characterizes Multiple Myeloma Patients Who Responded to up-Front Combination Therapy Including New Drugs

Carolina Terragna, Marina Martello, Barbara Santacroce, Vincenza Solli, Lucia Pantani, Elena Zamagni, Paola Tacchetti, Beatrice Anna Zannetti, Katia Mancuso, Giulia Marzocchi, Nicoletta Testoni, Gaia Ameli, Rosalinda Termini, Flores A Dico, Enrica Borsi, Giovanni Martinelli, Michele Cavo

Blood (2016) 128 (22): 2080.

https://doi.org/10.1182/blood.V128.22.2080.2080

Published: 2016

Journal Articles

Prospective Evaluation of 18F-FDG PET/CT As Predictor of Prognosis in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results from the Imaging Sus-Study of the EMN02/HO95 MM Randomized Phase III Trial

Blood (2016) 128 (22): 992.

https://doi.org/10.1182/blood.V128.22.992.992

Published: 2016

Journal Articles

An Amplicon-Targeted Ultra-Deep Sequencing Approach Reveals the Presence at the Onset of Multiple Myeloma and the Selection over Time of TP53 Sub-Clonal Variants, Which Adversely Influence Patients' Overall Survival

Carolina Terragna, PhD, Marina Martello, PhD, Mauro Procacci, Flavio Mignone, Annalisa Pezzi, PhD, Barbara Santacroce, Lucia Pantani, MD, Igor Saggese, Torsten Haferlach, Elena Zamagni, Enrica Borsi, PhD, Paola Tacchetti, MD, Beatrice A Zannetti, MD, Serena Rocchi, MD, Katia Mancuso, MD, Flores A Dico, Giovanni Martinelli, MD PhD, Michele Cavo

Blood (2015) 126 (23): 24.

https://doi.org/10.1182/blood.V126.23.24.24

Published: 2015

Journal Articles

Long-Term Clinical Outcomes of Allogeneic Stem Cell Transplantation in Multiple Myeloma

Elena Zamagni, Giuseppe Bandini, Annalisa Pezzi, PhD, Paola Tacchetti, Ilaria Rizzello, Lucia Pantani, Mario Arpinati, MD PhD, Beatrice A Zannetti, MD, Serena Rocchi, Mariarosaria Sessa, Annamaria Brioli, Katia Mancuso, Carolina Terragna, PhD, Nicoletta Testoni, Francesca Bonifazi, Michele Cavo, MD

Blood (2015) 126 (23): 1968.

https://doi.org/10.1182/blood.V126.23.1968.1968

Published: 2015

Journal Articles

Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome

Blood (2014) 124 (21): 484.

https://doi.org/10.1182/blood.V124.21.484.484

Published: 2014

Journal Articles

A Long Tail of Sub-Clonal TP53 Mutations Emerged By Ultra-Deep Sequencing of Newly Diagnosed Multiple Myeloma (MM)

Blood (2014) 124 (21): 3400.

https://doi.org/10.1182/blood.V124.21.3400.3400

Published: 2014

Journal Articles

The Presence of FDG PET/CT Focal, Not Osteolytic, Lesion(s) Identifies a Sub-Group of Patients with Smoldering Multiple Myeloma with High-Risk of Progression into Symptomatic Disease

Elena Zamagni, MD, Cristina Nanni, MD, Francesca Gay, MD, Annalisa Pezzi, Statistician, Marilena Bellò, MD, Ilaria Rambaldi, MD, Paola Tacchetti, MD, Annamaria Brioli, MD, Lucia Pantani, MD, Valeria Magarotto, MD, Beatrice Anna Zannetti, MD, Massimo Menga, MD, Giulia Marzocchi, PhD, Carolina Terragna, PhD, Katia Mancuso, MD, Antonio Palumbo, MD, Stefano Fanti, MD, Michele Cavo, MD

Blood (2014) 124 (21): 3371.

https://doi.org/10.1182/blood.V124.21.3371.3371

Published: 2014

Journal Articles

High-Throughput Molecular Profiling of Multiple Myeloma (MM) Clonotypic CD19+ B Cells Highlights Pathways Potentially Involved in the Disease Endurance

Marina Martello, PhD, Angela Flores Dico, Daniel Remondini, PhD, Giovanni Martinelli, MD, Enrica Borsi, PhD, Barbara Santacroce, Lucia Pantani, MD, Elena Zamagni, MD, Paola Tacchetti, MD, Annamaria Brioli, MD, Anna Beatrice Zannetti, MD, Katia Mancuso, MD, Serena Rocchi, MD, Annalisa Pezzi, Statistician, Nicoletta Testoni, PhD, Giulia Marzocchi, PhD, Gaia Ameli, Michele Cavo, MD, Carolina Terragna, PhD

Blood (2014) 124 (21): 2054.

https://doi.org/10.1182/blood.V124.21.2054.2054

Published: 2014

Journal Articles

Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDM

Annamaria Brioli, MD, Annalisa Pezzi, Statistician, Daniele Derudas, MD, Maria Concetta Petti, MD, Beatrice Anna Zannetti, MD, Felicetto Ferrara, MD, Serena Rocchi, MD, Francesco Nobile, MD, Anna Baraldi, MD, Pellegrino Musto, MD, Francesco Lanza, MD, Katia Mancuso, MD, Letizia Canepa, MD, Lucio Catalano, MD, Antonio Lazzaro, MD, Graziella Pinotti, MD, Mario Boccadoro, MD, Michele Cavo, MD

Blood (2014) 124 (21): 1182.

https://doi.org/10.1182/blood.V124.21.1182.1182

Published: 2014

Journal Articles

Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4

Carolina Terragna, PhD, Marina Martello, Enrica Borsi, PhD, Lucia Pantani, MD, Elena Zamagni, MD, Paola Tacchetti, MD, Brioli Annamaria, MD, Beatrice Anna Zannetti, MD, Flores Dico, Nicoletta Testoni, BS, Giulia Marzocchi, PhD, Katia Mancuso, MD, Serena Rocchi, MD, Giovanni Martinelli, MD, Michele Cavo, MD

Blood (2013) 122 (21): 1855.

https://doi.org/10.1182/blood.V122.21.1855.1855

Published: 2013

NARROW

Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

High Humoral Response after Anti-Sars-Cov-2 mRNA-Based Vaccines in Patients with Active Multiple Myeloma (MM) and Relationship with Disease Status/Line of Therapy

Negative Selective Pressure Exerted By Maintenance Therapy Promotes the Extinction of Sub-Clones Carrying High-Risk Lesions in Multiple Myeloma

Serum Free Light Chain Assay As an Additional Tool for Defining Response and Progressive Disease in Immunoglobulin Secretory Multiple Myeloma

A Maturation Index Defines Newly Diagnosed Multiple Myeloma Patients with Advanced Immunophenotypic and Molecular Differentiation Profiles Associated with Poor Prognosis

Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study

Bortezomib-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone before and after Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase 3 Gimema-MMY-3006 Study and Prognostic Score for Survival Outcomes

High-Risk Cytogenetics in Newly Diagnosed Multiple Myeloma: Prognostic Relevance of Co-Segregations and Analysis of the Role of Double Versus Single Autotransplantation

A Randomized Study of Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Cyclophosphamide-Dexamethasone Induction in Newly Diagnosed Myeloma Patients Eligible for Transplant: High Efficacy in High- and Standard-Risk Patients

A Branching Evolution Model at Relapse Characterizes Multiple Myeloma Patients Who Responded to up-Front Combination Therapy Including New Drugs

Prospective Evaluation of 18F-FDG PET/CT As Predictor of Prognosis in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results from the Imaging Sus-Study of the EMN02/HO95 MM Randomized Phase III Trial

An Amplicon-Targeted Ultra-Deep Sequencing Approach Reveals the Presence at the Onset of Multiple Myeloma and the Selection over Time of TP53 Sub-Clonal Variants, Which Adversely Influence Patients' Overall Survival

Long-Term Clinical Outcomes of Allogeneic Stem Cell Transplantation in Multiple Myeloma

Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome

A Long Tail of Sub-Clonal TP53 Mutations Emerged By Ultra-Deep Sequencing of Newly Diagnosed Multiple Myeloma (MM)

The Presence of FDG PET/CT Focal, Not Osteolytic, Lesion(s) Identifies a Sub-Group of Patients with Smoldering Multiple Myeloma with High-Risk of Progression into Symptomatic Disease

High-Throughput Molecular Profiling of Multiple Myeloma (MM) Clonotypic CD19+ B Cells Highlights Pathways Potentially Involved in the Disease Endurance

Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDM

Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only